相关实验视频
Updated: Jul 10, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
脑卒中后高血糖的管理:TEXAIS随机临床试验的结果
Christopher F Bladin1,2, Ngai Wah Cheung3, Helen M Dewey1
1Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Department of Neurology, Monash University, Clayton, Victoria, Australia (C.F.B., H.M.D., P.M.C.C.).
Stroke
|November 27, 2023
概括
埃克萨纳提德并没有改善急性缺血性中风患者的神经结果,但显著降低了高血糖症,而不会导致低血糖症. 在中风中对GLP-1激动剂进行进一步的试验是有必要的.
科学领域:
- 神经学 神经学
- 内分泌学 在内分泌学.
- 临床试验 临床试验
背景情况:
- 在急性缺血性中风中,高血糖会使结果恶化,并降低治疗效率.
- 胰岛素治疗中风后高血糖症带来低血糖症的风险.
- 作为GLP-1受体激动剂的exenatide因其改善中风结果和管理高血糖症的潜力而受到研究.
研究的目的:
- 为了评估exenatide在改善急性缺血性中风患者神经结果方面的疗效.
- 为了评估exenatide控制中风后高血糖的能力,低血糖的风险最小.
主要方法:
- 在急性缺血性中风 (TEXAIS) 中使用exenatide的治疗试验是一项2期随机临床试验.
- 350名患有急性缺血性中风的成年患者接受了exenatide或标准护理5天.
- 主要结局是7天后NIH中风量表得分改善8分;安全结局包括高血糖和低血糖.
主要成果:
- 与标准护理相比,exenatide并没有显著改善主要结局 (61.2%与56.7%相比).
- 埃克西纳提德显著降低了每天高血糖的频率.
- 在exenatide组中没有观察到低血糖症的发作;报告有轻微的恶心和吐.
结论:
- 在急性缺血性中风患者中,exenatide在7天内没有改善神经功能障碍.
- 埃克萨纳提德在降低中风后高血糖事件的安全性和有效性被证明是没有诱导低血糖的.
- 建议进行更大规模的临床试验,研究急性中风的GLP-1主动剂,如埃克萨纳提德.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
289
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
289
01:15Hypoglycemia and Glucagon
272
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
272
01:30Acute Pancreatitis II: Clinical Manifestations and Management
126
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
126
01:22Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209